GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Stevanato Group SPA (NYSE:STVN) » Definitions » PB Ratio

Stevanato Group SPA (Stevanato Group SPA) PB Ratio : 4.69 (As of May. 12, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Stevanato Group SPA PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-05-12), Stevanato Group SPA's share price is $21.82. Stevanato Group SPA's Book Value per Share for the quarter that ended in Dec. 2023 was $4.65. Hence, Stevanato Group SPA's PB Ratio of today is 4.69.

Good Sign:

Stevanato Group SPA stock PB Ratio (=4.69) is close to 1-year low of 4.69

The historical rank and industry rank for Stevanato Group SPA's PB Ratio or its related term are showing as below:

STVN' s PB Ratio Range Over the Past 10 Years
Min: 3.91   Med: 6.2   Max: 18.75
Current: 4.69

During the past 6 years, Stevanato Group SPA's highest PB Ratio was 18.75. The lowest was 3.91. And the median was 6.20.

STVN's PB Ratio is ranked worse than
76.89% of 792 companies
in the Medical Devices & Instruments industry
Industry Median: 2.235 vs STVN: 4.69

During the past 12 months, Stevanato Group SPA's average Book Value Per Share Growth Rate was 16.70% per year. During the past 3 years, the average Book Value Per Share Growth Rate was 53.70% per year.

During the past 6 years, the highest 3-Year average Book Value Per Share Growth Rate of Stevanato Group SPA was 58.50% per year. The lowest was 53.70% per year. And the median was 56.10% per year.

Back to Basics: PB Ratio


Stevanato Group SPA PB Ratio Historical Data

The historical data trend for Stevanato Group SPA's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Stevanato Group SPA PB Ratio Chart

Stevanato Group SPA Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PB Ratio
Get a 7-Day Free Trial - - 6.24 4.51 5.87

Stevanato Group SPA Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.51 6.21 7.51 6.74 5.87

Competitive Comparison of Stevanato Group SPA's PB Ratio

For the Medical Instruments & Supplies subindustry, Stevanato Group SPA's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Stevanato Group SPA's PB Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Stevanato Group SPA's PB Ratio distribution charts can be found below:

* The bar in red indicates where Stevanato Group SPA's PB Ratio falls into.



Stevanato Group SPA PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Stevanato Group SPA's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Dec. 2023)
=21.82/4.652
=4.69

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Stevanato Group SPA  (NYSE:STVN) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Stevanato Group SPA PB Ratio Related Terms

Thank you for viewing the detailed overview of Stevanato Group SPA's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Stevanato Group SPA (Stevanato Group SPA) Business Description

Traded in Other Exchanges
Address
Via Molinella 17, Piombino Dese, Padua, ITA, 35017
Stevanato Group SPA is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. Stevanato's revenue is geographically diversified, with 60% of sales from Europe, the Middle East and Africa (EMEA), 27% in North America, 10% in Asia-Pacific (APAC), and 3% from South America. It has two segments Biopharmaceutical and Diagnostic Solutions and Engineering.